Clinical trialNCT04641871CompletedPhase 1Interventional

Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies

SponsorSymphogen A/SEnrollment78Metastatic CancerSolid Tumor

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The study will evaluate the preliminary efficacy of 3 combinations (Sym021+Sym022, Sym021+Sym023 and Sym021+Sym023+irinotecan) in patients with biliary tract carcinomas (BTC) and with esophageal squamous cell carcinoma (ESCC) by assessing overall response rates (ORRs) per Investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 The study will also evaluate the safety and tolerability profile of the 3 combinations

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Nehal Lakhani, MD
START Midwest
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

17 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

Princess Margaret Cancer Centre
Toronto, Ontario, Canada

France

Centre Georges-François Leclerc, Department of Medical Oncology
Dijon, France
Institut de Cancerologie de L'Ouest
Saint-Herblain, France

Spain

Vall D'Hebron Institute of Oncology
Barcelona, Spain
Hospital Universitario San Carlos
Madrid, Spain

United States

University of Colorado
Aurora, Colorado, United States
Mayo Clinic - Jacksonville
Jacksonville, Florida, United States
Moffitt Cancer Center
Tampa, Florida, United States
University of Chicago
Chicago, Illinois, United States
University of Kansas Medical Center (kumc)
Westwood, Kansas, United States
Start Midwest
Grand Rapids, Michigan, United States
Mayo Clinic
Rochester, Minnesota, United States
Mount Sinai - Prime
New York, New York, United States
Montefiore Medical Center Prime
The Bronx, New York, United States
University of Cincinnati Medical Center
Cincinnati, Ohio, United States
Md Anderson
Houston, Texas, United States
Virginia Cancer Specialists, Pc
Fairfax, Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Irinotecan →Sym021Sym022Sym023

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 12 Oct 2020
Primary completion: 3 Jun 2024
Completion: 3 Jun 2024
Last update posted: 26 Jun 2024
Registered enrollment: 78
Registry id: NCT04641871

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.